Know Cancer

or
forgot password

Phase II Study of Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors


Phase 2
18 Years
80 Years
Not Enrolling
Both
Pancreatic Cancer

Thank you

Trial Information

Phase II Study of Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors


Patients will need to come for 24 study visits in all. Most study visits will take about 2
hours. At some of these study visits, the doctor

- Will do a physical exam

- Will take blood for routine lab tests

- Will do a urinalysis

- Will administer study medication Some study visits may be longer because patient will
have a CT scan or an MRI.

At patient's last visit, they will have a CT scan or MRI.

After treatment starts, patient will:

- Have their blood pressure monitored with every dose of Avastin® (about every 2 weeks).

- Have a history and physical with every chemotherapy cycle (about every 4 weeks).

- Have their blood taken for routine blood tests with every chemotherapy cycle (about
every 4 weeks).

- Have a CT scan or MRI during every other cycle (about every 8 weeks).

- Have a MUGA scan during every 4 cycles (about 16 weeks).

- Have blood taken for tumor markers during every cycle only if their markers were high
at baseline.

- Patients will receive study medication to treat their cancer:

- Fluorouracil on days 1 through 5 of each cycle through cycle 12

- Doxorubicin on day 1 of each cycle through cycle 8

- Streptozocin on days 1 through 5 of each cycle through cycle 12

- Avastin® on days 1 and 15 of each cycle through cycle 12


Inclusion Criteria:



- Patients must have locally advanced (unresectable) or metastatic, well or moderately
differentiated pancreatic endocrine tumors.

- Measurable disease on CT scan or MRI.

- Age ≥ 18 years and ≤ 80 years.

- Use of effective means of contraception (men and women) in subjects of child-bearing
potential

- Adequate renal function (serum creatinine ≤1.5, urine protein:creatinine ratio <1.0
or urine dipstick for proteinuria < 2+ (patients discovered to have ≥ 2+ proteinuria
on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must
demonstrate ≤ 1 g of protein in 24 hours to be eligible).

- Adequate hepatic function (bilirubin ≤2.0, AST and ALT ≤ 3x ULN.

- Adequate hematologic function (WBC ≥ 3,000, ANC ≥ 1500, platelets ≥ 100,000)

Exclusion Criteria:

- Prior therapy with fluorouracil, doxorubicin, streptozocin or avastin

- Ejection fraction on MUGA <50%

- ECOG performance status > 2

- Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study other than a Genentech-sponsored avastin
cancer study

- Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or
diastolic blood pressure > 100 mmHg on antihypertensive medications)

- Any prior history of hypertensive crisis or hypertensive encephalopathy

- Unstable angina

- New York Heart Association (NYHA) Grade II or greater congestive heart failure

- History of myocardial infarction or unstable angina within 6 months prior to study
enrollment

- History of stroke or transient ischemic attack within 6 months prior to study
enrollment

- Significant vascular disease (e.g., aortic aneurysm, aortic dissection)

- Symptomatic peripheral vascular disease

- Evidence of bleeding diathesis or coagulopathy

- Presence of central nervous system or brain metastases

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day 0, anticipation of need for major surgical procedure during the course
of the study

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to study enrollment

- Pregnant (positive pregnancy test) or lactating. Use of effective means of
contraception (men and women) in subjects of child-bearing potential

- Proteinuria at screening as demonstrated by either

- Urine protein: creatinine (UPC) ratio ≥ 1.0 at screening OR

- Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria
on dipstick urinalysis at baseline should undergo a 24 hour urine collection and
must demonstrate ≤ 1g of protein in 24 hours to be eligible).

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to Day 0

- Evidence of duodenal invasion on CT scan, MRI, or endoscopy

- Known hypersensitivity to any component of avastin

- Serious, non-healing wound, ulcer, or bone fracture

- Inability to comply with study and/or follow-up procedures

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of Participants With Progression Free Survival (PFS) at 12 Months

Outcome Description:

We planned to calculate the One Year Progression Free Survival rate. The event for PFS analyses was the first occurrence of disease progression or death and patients who did not progress or died would be censored at the date of last tumor evaluation (e.g. one-year).

Outcome Time Frame:

12 months

Safety Issue:

No

Principal Investigator

Larry Kvols, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

H. Lee Moffitt Cancer Center and Research Institute

Authority:

United States: Institutional Review Board

Study ID:

MCC-14961

NCT ID:

NCT00609765

Start Date:

August 2007

Completion Date:

March 2008

Related Keywords:

  • Pancreatic Cancer
  • advanced
  • unresectable
  • metastatic
  • endocrine
  • tumors
  • Endocrine Gland Neoplasms
  • Pancreatic Neoplasms
  • Adenoma, Islet Cell

Name

Location

H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida  33612